Phase III clinical trial results of ipilimumab treatment of metastatic melanoma demonstrated that ipilimumab (with or without a gp100 peptide vaccine) provided a significant increase in overall survival rate compared to gp100 alone. The gene discussed is PMEL; the disease is metastatic melanoma.